Mindray seals $35.5M deal for Dragonbio's orthopedics implant line

Six weeks after the initial announcement, Chinese device giant Mindray Medical ($MR) has completed its $35.5 million bid to buy Wuhan Dragonbio Surgical Implant Co.'s orthopedics business. Dragonbio makes spine, joint, and trauma-related surgical orthopedics implants. The space represents a major growth area for Mindray and others. Frost & Sullivan estimated, for example, that the Chinese orthopedics market was worth $1.1 billion in 2010. Add to that a projected 18% annual growth rate, and Mindray will be off and running. Release